Etevritamab - Amgen
Alternative Names: AMG-596Latest Information Update: 08 Nov 2024
At a glance
- Originator Amgen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 28 Oct 2024 Amgen terminates a phase I trial in Glioblastoma (Newly diagnosed, Metastatic disease, Recurrent) in USA, Australia, France, Germany, Netherlands and Spain (IV) due to business decision (NCT03296696)
- 09 Feb 2021 Discontinued - Phase-I for Glioblastoma (Metastatic disease, Newly diagnosed) in USA, France, Netherlands, Spain, Germany (IV)
- 09 Feb 2021 Discontinued - Phase-I for Glioblastoma (Metastatic disease, Recurrent) in France, Germany, Netherlands, Spain, USA (IV)